Literature DB >> 27452524

CD84 mediates CLL-microenvironment interactions.

A Marom1, A F Barak1, M P Kramer1, H Lewinsky1, I Binsky-Ehrenreich1, S Cohen1, A Tsitsou-Kampeli1, V Kalchenko2, Y Kuznetsov2, V Mirkin3, N Dezorella4, M Shapiro4, P L Schwartzberg5, Y Cohen6, L Shvidel3, M Haran3, S Becker-Herman1, Y Herishanu4, I Shachar1.   

Abstract

Chronic lymphocytic leukemia (CLL) is a malignant disease of small mature lymphocytes. Signals from the CLL microenvironment promote progression of the disease and induce drug resistance. This phenomenon is largely dependent on direct contact between the malignant B cells and stromal cells. CD84 belongs to the signaling lymphocyte activation molecule family of immunoreceptors, which self-associates, forming an orthogonal homophilic dimer. We therefore hypothesized that CD84 may bridge between CLL cells and their microenvironment, promoting cell survival. Our in vitro results show that CD84 expressed on CLL cells interact with CD84 expressed on cells in their microenvironment, inducing cell survival in both sides. Blocking CD84 in vitro and in vivo disrupt the interaction of CLL cells with their microenvironment, resulting in induced cell death. Thus, our findings suggest novel therapeutic strategies based on the blockade of this CD84-dependent survival pathway.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27452524     DOI: 10.1038/onc.2016.238

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

1.  CD84 functions as a homophilic adhesion molecule and enhances IFN-gamma secretion: adhesion is mediated by Ig-like domain 1.

Authors:  M Martin; X Romero; M A de la Fuente; V Tovar; N Zapater; E Esplugues; P Pizcueta; J Bosch; P Engel
Journal:  J Immunol       Date:  2001-10-01       Impact factor: 5.422

2.  Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch".

Authors:  Neil E Kay; Tait D Shanafelt; Ann K Strege; Yean K Lee; Nancy D Bone; Azra Raza
Journal:  Leuk Res       Date:  2007-01-22       Impact factor: 3.156

3.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

Authors:  Bradley T Messmer; Davorka Messmer; Steven L Allen; Jonathan E Kolitz; Prasad Kudalkar; Denise Cesar; Elizabeth J Murphy; Prasad Koduru; Manlio Ferrarini; Simona Zupo; Giovanna Cutrona; Rajendra N Damle; Tarun Wasil; Kanti R Rai; Marc K Hellerstein; Nicholas Chiorazzi
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

4.  CD84 is a survival receptor for CLL cells.

Authors:  I Binsky-Ehrenreich; A Marom; M C Sobotta; L Shvidel; A Berrebi; I Hazan-Halevy; S Kay; A Aloshin; I Sagi; D M Goldenberg; L Leng; R Bucala; Y Herishanu; M Haran; I Shachar
Journal:  Oncogene       Date:  2013-02-25       Impact factor: 9.867

5.  Bone marrow expression of CCL3 is not correlated with the extent of lytic bone lesions.

Authors:  Yossi Cohen; Odit Gutwein; Osnat Garach-Jehoshua; Adina Bar-Haim; Abraham Kornberg
Journal:  Acta Haematol       Date:  2014       Impact factor: 2.195

Review 6.  Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.

Authors:  Michael Hallek
Journal:  Am J Hematol       Date:  2015-05       Impact factor: 10.047

7.  Optimal germinal center responses require a multistage T cell:B cell adhesion process involving integrins, SLAM-associated protein, and CD84.

Authors:  Jennifer L Cannons; Hai Qi; Kristina T Lu; Mala Dutta; Julio Gomez-Rodriguez; Jun Cheng; Edward K Wakeland; Ronald N Germain; Pamela L Schwartzberg
Journal:  Immunity       Date:  2010-02-11       Impact factor: 31.745

8.  CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.

Authors:  Antonella Zucchetto; Dania Benedetti; Claudio Tripodo; Riccardo Bomben; Michele Dal Bo; Daniela Marconi; Fleur Bossi; Debora Lorenzon; Massimo Degan; Francesca Maria Rossi; Davide Rossi; Pietro Bulian; Vito Franco; Giovanni Del Poeta; Silvia Deaglio; Gianluca Gaidano; Francesco Tedesco; Fabio Malavasi; Valter Gattei
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

Review 9.  Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.

Authors:  Elisa ten Hacken; Jan A Burger
Journal:  Pharmacol Ther       Date:  2014-07-19       Impact factor: 12.310

10.  IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival.

Authors:  Inbal Binsky; Michal Haran; Diana Starlets; Yael Gore; Frida Lantner; Nurit Harpaz; Lin Leng; David M Goldenberg; Lev Shvidel; Alain Berrebi; Richard Bucala; Idit Shachar
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-08       Impact factor: 11.205

View more
  12 in total

1.  FUS(1-359) transgenic mice as a model of ALS: pathophysiological and molecular aspects of the proteinopathy.

Authors:  Sergei Y Funikov; Alexander P Rezvykh; Pavel V Mazin; Alexey V Morozov; Andrey V Maltsev; Maria M Chicheva; Ekaterina A Vikhareva; Mikhail B Evgen'ev; Aleksey A Ustyugov
Journal:  Neurogenetics       Date:  2018-07-07       Impact factor: 2.660

2.  CD74 is a novel transcription regulator.

Authors:  Naama Gil-Yarom; Lihi Radomir; Lital Sever; Matthias P Kramer; Hadas Lewinsky; Chamutal Bornstein; Ronnie Blecher-Gonen; Zohar Barnett-Itzhaki; Vita Mirkin; Gilgi Friedlander; Lev Shvidel; Yair Herishanu; Elias J Lolis; Shirly Becker-Herman; Ido Amit; Idit Shachar
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-28       Impact factor: 11.205

3.  CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.

Authors:  Hadas Lewinsky; Avital F Barak; Victoria Huber; Matthias P Kramer; Lihi Radomir; Lital Sever; Irit Orr; Vita Mirkin; Nili Dezorella; Mika Shapiro; Yosef Cohen; Lev Shvidel; Martina Seiffert; Yair Herishanu; Shirly Becker-Herman; Idit Shachar
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

4.  T Cells Regulate Peripheral Naive Mature B Cell Survival by Cell-Cell Contact Mediated through SLAMF6 and SAP.

Authors:  Lihi Radomir; Sivan Cohen; Matthias P Kramer; Eszter Bakos; Hadas Lewinsky; Avital Barak; Ziv Porat; Richard Bucala; Polina Stepensky; Shirly Becker-Herman; Idit Shachar
Journal:  J Immunol       Date:  2017-09-13       Impact factor: 5.422

5.  Bone marrow dendritic cells support the survival of chronic lymphocytic leukemia cells in a CD84 dependent manner.

Authors:  Avital F Barak; Hadas Lewinsky; Michal Perpinial; Victoria Huber; Lihi Radomir; Mattias P Kramer; Lital Sever; Yochai Wolf; Mika Shapiro; Yair Herishanu; Steffen Jung; Shirly Becker-Herman; Idit Shachar
Journal:  Oncogene       Date:  2019-11-26       Impact factor: 9.867

Review 6.  SLAMF6 in health and disease: Implications for therapeutic targeting.

Authors:  Burcu Yigit; Ninghai Wang; Roland W Herzog; Cox Terhorst
Journal:  Clin Immunol       Date:  2018-10-23       Impact factor: 3.969

Review 7.  Leukaemia: a model metastatic disease.

Authors:  Andrew E Whiteley; Trevor T Price; Gaia Cantelli; Dorothy A Sipkins
Journal:  Nat Rev Cancer       Date:  2021-05-05       Impact factor: 69.800

Review 8.  Signaling lymphocytic activation molecules Slam and cancers: friends or foes?

Authors:  Gregory Fouquet; Ingrid Marcq; Véronique Debuysscher; Jagadeesh Bayry; Amrathlal Rabbind Singh; Abderrahmane Bengrine; Eric Nguyen-Khac; Mickael Naassila; Hicham Bouhlal
Journal:  Oncotarget       Date:  2018-02-26

9.  Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics.

Authors:  Hamad Alshetaiwi; Nicholas Pervolarakis; Laura Lynn McIntyre; Dennis Ma; Quy Nguyen; Jan Akara Rath; Kevin Nee; Grace Hernandez; Katrina Evans; Leona Torosian; Anushka Silva; Craig Walsh; Kai Kessenbrock
Journal:  Sci Immunol       Date:  2020-02-21

10.  The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer.

Authors:  De-Wei Wu; Po-Lin Lin; Lee Wang; Chi-Chou Huang; Huei Lee
Journal:  Theranostics       Date:  2017-02-27       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.